Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

• Status: Completed
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: All

Summary

A clinical trial to determine the effectiveness and safety of AUY922 compared to other drugs known to be effective against gastric cancer in second line therapy for patients who have failed one line of chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Docetaxel; Irinotecan

Criteria

Inclusion Criteria:

• Radiologically confirmed advanced gastric cancer

• One previous line of chemotherapy

• Progressive disease

• One measurable lesion

• Blood tests within protocol ranges

• (WHO) Performance Status ≤ 1

• Able to sign informed consent

Exclusion Criteria:

• No symptomatic brain metastases

• No coumarin type anticoagulants

• No liver or kidney disease

• No impaired heart function

• No pregnant or lactating women

Other protocol-defined inclusion/exclusion criteria may apply